selurampanel: anticonvulsant that antagonizes both AMPA and kainate receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 45381907 |
CHEMBL ID | 3545042 |
SCHEMBL ID | 1660562 |
MeSH ID | M000597226 |
Synonym |
---|
n-[7-isopropyl-6-(2-methyl-2h-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl]-methanesulfonamide |
MCECSFFXUPEPDB-UHFFFAOYSA-N |
7wg1mr7dar , |
bgg 492a |
selurampanel [inn] |
selurampanel |
bgg 492 |
unii-7wg1mr7dar |
912574-69-7 |
bgg492 |
selurampanel [who-dd] |
bgg-492 |
n-(6-(1-methyl-1h-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2h)-yl)methanesulfonamide |
SCHEMBL1660562 |
CHEMBL3545042 |
DTXSID00238467 |
DB12367 |
AKOS032946688 |
n-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1h-quinazolin-3-yl]methanesulfonamide |
Q21098868 |
SB17404 |
HY-105860 |
CS-0026799 |
Selurampanel (BGG492) is an experimental competitive AMPA antagonist currently in clinical trials.
Excerpt | Reference | Relevance |
---|---|---|
"Selurampanel (BGG492) is an experimental competitive AMPA antagonist currently in clinical trials." | ( BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Faught, E, 2014) | 1.56 |
Excerpt | Reference | Relevance |
---|---|---|
" Adverse events were reported by 80%, 56%, and 60% of BGG492, sumatriptan, and placebo subjects, respectively." | ( Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Brand, R; Campos, V; Diener, HC; Evers, S; Göbel, H; Gomez-Mancilla, B; Hariry, S; Johns, D; Jürgens, TP; Kalkman, HO; Pezous, N; Sommer, C; Sommer, M; Straube, A, 2014) | 0.4 |
" Safety was assessed by recording all adverse events (AEs)." | ( Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study. Abd-Elaziz, K; Derne, C; Johns, D; Kucher, K; Langguth, B; Pfister, CU; Sverdlov, O; Wagner, F, 2021) | 0.88 |
Excerpt | Reference | Relevance |
---|---|---|
" Guided by ionic liquid structure, in vivo profiles ranged from rapid bioavailability and high maximal plasma concentrations to sustained patterns." | ( Mapping the pharmaceutical design space by amorphous ionic liquid strategies. Balk, A; Bruhn, H; Dekant, W; Galli, B; Holzgrabe, U; Lühmann, T; Meinel, L; Merget, B; Picard, F; Raccuglia, M; Saedtler, M; Sotriffer, C; Stopper, H; Walid, E; Widmer, T; Wiest, J, 2017) | 0.46 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (88.89) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.21) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (44.44%) | 5.53% |
Reviews | 3 (33.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 2 (22.22%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |